For the estimated one in 100 people worldwide living with celiac disease, the burden of their diagnosis extends far beyond the kitchen table. While the condition has been recognized for decades as a serious, systemic autoimmune disorder, the standard of care has remained stagnant. For millions of patients, the only available "treatment" is a lifelong, strictly enforced gluten-free diet. This status quo places an enormous, often unsustainable, psychological and physical burden on patients and their families, as the volatility of modern food supply chains makes true avoidance of gluten a constant, stressful, and often unsuccessful endeavor.
However, the medical and pharmaceutical communities are entering a pivotal era. The perception of celiac disease is shifting; it is no longer viewed merely as a dietary inconvenience to be managed at home, but as a significant clinical challenge requiring robust, science-driven therapeutic intervention. This fundamental shift in perspective has opened the door to a new chapter of innovation, with companies like First Tracks Biotherapeutics leading the charge to develop disease-modifying therapies.
The Limits of Diet Alone: An Unmet Clinical Need
The reliance on a gluten-free diet is increasingly viewed by gastroenterologists and researchers as an insufficient response to a systemic autoimmune disease.
"Gluten is difficult to avoid because it’s in 80% of our foodstuffs. Patients also must worry about cross-contact when eating out," explains Marilyn Geller, CEO of the Celiac Disease Foundation. "Too often, patients are told to go gluten-free but do not get professional support because dietitian care is typically not covered by insurance."
The consequences of this "do-it-yourself" approach are clear. While many patients experience an improvement in their initial, acute symptoms upon eliminating gluten, a significant subset continues to struggle with chronic, debilitating issues—including nausea, abdominal pain, bloating, and fatigue. These persistent symptoms are often clear clinical indicators of ongoing intestinal injury. Even with the most disciplined adherence to a gluten-free lifestyle, the reality of accidental exposure to gluten—whether through manufacturing errors or shared kitchen surfaces—keeps patients in a state of constant, low-grade inflammation. For these individuals, diet alone is failing to address the underlying inflammatory cascades that drive the disease.
A Mechanism-Driven Approach to Treatment
For years, early drug development in the celiac space focused on the "neutralization" of gluten before it could trigger an immune response. These efforts primarily sought to degrade gluten proteins before they reached the small intestine. While conceptually promising, these approaches often failed to account for the complexity of the systemic immune response.
Modern research has provided a more nuanced understanding: celiac disease is not just a reaction to a protein; it is a complex, immune-mediated condition fueled by broader inflammatory signaling pathways. Central to this are cytokines like interleukin-15 (IL-15) and IL-2, which act as catalysts for the proliferation of pathogenic immune cells.
First Tracks Biotherapeutics is moving away from the "neutralization" model and toward a mechanism-driven approach. Their investigational antibody, ANB033, targets CD122—the shared beta subunit of the IL-15 and IL-2 receptors. By blocking this specific pathway, the drug aims to dampen the overactive immune signals that cause intestinal damage. This approach is designed to stop the proliferation of CD8+ and CD4+ T cells and natural killer (NK) cells—the very cells responsible for the mucosal injury that defines the celiac pathology.
Chronology of the Celiac Treatment Evolution
The path to modern celiac therapeutics has been a slow climb, marked by a transition from dietary management to biological discovery:
- Mid-20th Century: The medical community confirms the link between wheat consumption and villous atrophy in the small intestine. The "Gluten-Free Diet" becomes the gold standard.
- 1990s–2000s: The genetic and immunological components of celiac disease are mapped. The role of HLA-DQ2/DQ8 and the activation of T-cells by deamidated gluten peptides are identified.
- 2010–2020: The "Neutralization Era." Numerous clinical trials test enzymes intended to break down gluten in the stomach. Most yield limited clinical success in real-world settings, highlighting the need for systemic, not just intraluminal, treatments.
- 2021–Present: The "Immunotherapy Era." Attention shifts toward modulating the body’s inflammatory response. Research into the IL-15 and IL-2 signaling pathways gains traction, leading to the development of targeted biological therapies like ANB033.
Supporting Data: Why Targeting CD122 Matters
The rationale for targeting CD122 is rooted in the specific biology of celiac disease. In patients with the condition, the ingestion of gluten triggers the release of IL-15. This cytokine is a potent survival factor for intraepithelial lymphocytes (IELs). When these cells are chronically activated, they begin to destroy the epithelial lining of the gut, leading to the malabsorption and inflammation characteristic of the disease.
Preclinical data surrounding ANB033 suggests a differentiated path. Unlike earlier, narrower approaches that inhibited a single cytokine, the targeting of the CD122 receptor provides a more comprehensive blockade of both IL-15 and IL-2. By modulating this dual-pathway, the therapeutic potential for maintaining remission—even in the event of accidental gluten exposure—is significantly higher. For the patient, this means a shift from "avoidance at all costs" to a more stable, protected internal environment.
Rethinking Trial Design: Innovation in Clinical Research
One of the greatest barriers to bringing a celiac drug to market has been the difficulty of trial design. Historically, testing the efficacy of a drug required a "gluten challenge"—intentionally feeding patients gluten to see if the drug worked. This process is both painful for the patient and difficult to standardize.
First Tracks Biotherapeutics is disrupting this model. Their current Phase 1b trial is enrolling patients with established intestinal injury and, importantly, is focusing on real-world outcomes. By incorporating the "Celiac Disease Symptom Diary"—an instrument developed in line with FDA guidelines—the company is ensuring that the data collected actually reflects the lived experience of the patient.
"By including patients with established injury in an early-phase trial, we are innovating traditional celiac trials and taking advantage of real-world needs, broadening the relevance of the study," the company notes. The study aims to provide, for the first time, a clear look at how histological changes (the healing of the intestine) correlate with the reduction of patient-reported symptoms like abdominal pain and nausea.
Implications for the Future of Gastroenterology
If successful, the introduction of a biological therapy for celiac disease would mark the most significant paradigm shift in the field since the identification of gluten as the trigger.
"Historically, physicians have had limited tools beyond referring patients back to dietary counseling," notes Dr. Paul Lizzul, Chief Medical Officer at First Tracks Biotherapeutics. "An effective therapy would make celiac a disease that gastroenterologists can actively treat and monitor."
The implications are profound. A licensed therapy would:
- Change the Standard of Care: Move the baseline expectation from "dietary adherence" to "clinical remission."
- Validate the Patient Experience: For decades, many patients have felt marginalized by the medical system. A drug would provide concrete evidence that their suffering is recognized as a valid medical condition worthy of pharmaceutical intervention.
- Economic Shift: Currently, the costs of celiac disease—frequent blood tests, biopsy follow-ups, and the personal expense of a gluten-free diet—are largely borne by the patient. A validated treatment could pave the way for insurance coverage and a more formalized system of care.
"The first therapy to cross the line could change the field," concludes Marilyn Geller. "It would help establish celiac as a serious medical condition with options beyond a restrictive diet and open the door for what comes next."
As we look toward 2026 and the expected data readouts, the medical community stands at a crossroads. The future of celiac treatment will not be defined by statistical significance alone, but by whether new therapies can fundamentally improve the daily burden of living with this disease. For those who have spent years navigating the hidden dangers of the grocery aisle, the prospect of a medical solution is not just a scientific milestone—it is a long-overdue promise of a better quality of life.
Dr. Paul Lizzul is the Chief Medical Officer at First Tracks Biotherapeutics, a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. Marilyn Geller serves as an advisor to First Tracks Bio.
